linjc16/ctgov huggingface dataset:
Black Adolescent & Entertainment Study

Study Overview
=================
Brief Summary
-----------------
The study is being conducted to obtain adolescent girls' thoughts and opinions on relationship and communication styles are shown on television.

Official Title
-----------------
The Effect of Food Marketing and Attentional Biases on Eating Behaviors in African American Adolescent Girls

Conditions
-----------------
Obesity, Childhood

Intervention / Treatment
-----------------
* Other: Observation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female, Self-identify as African American or Black, 12 to 17 years of age at the start of the study, Presence of obesity by virtue of a body mass index (BMI) ≥ 95th percentile for age and sex or non-overweight by virtue of a BMI of at least the5th percentile, but below the 85th percentile, for age and sex,118 and English speaking. Exclusion Criteria: Reports of the presence of a major chronic medical illness: renal, hepatic, gastrointestinal, endocrinologic (e.g., Cushing syndrome, hyper- or hypothyroidism), hematological problems or pulmonary disorders (other than asthma not requiring continuous medication), Individuals who self-report major depressive disorder, psychoses, current substance or alcohol use disorder, or any other psychiatric disorder that, in the opinion of the investigators, would impede competence or compliance or possibly hinder completion of the study. Current, regular use of prescription medications that affect appetite, mood, or body weight: currently prescribed serotonin re-uptake inhibitors (SSRIs), neuroleptics, tricyclics, stimulants, or any other medication known to affect appetite, mood, or body weight. Oral contraceptive use will be permitted, provided the contraceptive has been used for at least two months before the study visit, Failure to provide a rating of 6 or more on at least 50% of food items on the Food Preferences Questionnaire (Appendix F); exceptions may be given for restrictions due to religious practices or food allergies, if food items can be replaced with items of equivalent macronutrient content.

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Observation|Examine thoughts and behaviors|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Total energy consumption | Total energy consumption from a laboratory test meal | Day 1 | 
| Macronutrient intake | Total energy intake from fat, sugar, and sodium | Day 1 |
Evaluation of Carbohydrates - Glycemic Index

Study Overview
=================
Brief Summary
-----------------
This study is an open-label with a randomized, cross-over design using standard GI methodology.

Official Title
-----------------
Evaluation of Carbohydrates: Glycemic Index of Nutrition Product Formulation

Conditions
-----------------
Glycemic Index

Intervention / Treatment
-----------------
* Other: Control Meal 1
* Other: Control Meal 2
* Other: Experimental Nutritional Product


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects are males or non-pregnant females in good health Subjects must be eligible to receive income in Canada and must demonstrate OHIP or equivalent medical coverage. Exclusion Criteria: Subjects with any type of food allergy or known history of AIDS, hepatitis, diabetes or a heart condition Subjects taking medication, or with any condition which might, in the opinion of the PI either make participation dangerous to the subject or to others or affect the results

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Control Meal 1<br>Control carbohydrate solution | Other: Control Meal 1<br>* carbohydrate test meal<br>|
| Active Comparator: Control Meal 2<br>Control carbohydrate solution | Other: Control Meal 2<br>* carbohydrate test meal<br>|
| Experimental: Experimental Nutritional Product<br>Study nutritional formulation | Other: Experimental Nutritional Product<br>* ready to drink nutritional formulation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood glucose response curve | area under the curve | 0 to 120 minutes |
Negative Oral Contrast Agents Utilization in PET/CT Studies

Study Overview
=================
Brief Summary
-----------------
To compare the performance of different negative oral contrast agents in bowel distension in patient referred for PET/CT studies for various causes aiming for identification of ideal oral contrast agent(OCA).

Detailed Description
-----------------
Evaluation of gastrointestinal pathology depends on adequate bowel distention, which optimizes resolution of the bowel wall and contents. Traditionally, high-attenuation oral Contrast material in the form of iodine solutions or barium suspensions has been used to obtain bowel distension in MDCT examinations Traditional high-contrast oral agents like iodine solutions, and barium suspensions which due to overcorrection problems in PET-CT interpretation lowers the accuracy of diagnosis. Negative oral contrast agents like water, air, fat containing agents used with 12.5% corn oil and polyethylene glycol has been used in radiological studies. Milk with 4% fat content has also been tested out in radiological studies and found to be effective. As it is more easily available, palatable, and acceptable especially, by children it needed to be tested in the visualization of the GIT in the PET-CT studies compared to other negative contrast agents.

Official Title
-----------------
Negative Oral Contrast Agents Utilization in PET/CT Studies

Conditions
-----------------
PET/CT, Oral Contrast

Intervention / Treatment
-----------------
* Other: oral contrast


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all patients referred to our unit for PET/CT study for various causes Exclusion Criteria: Patients with GIT disease. Pregnancy and lactation. Severely ill patients.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Water<br>Patients who ingested only water as an oral contrast | Other: oral contrast<br>* negative oral contrast utilization in PET/CT studies<br>|
| Milk<br>Patients who ingested milk as an oral contrast | Other: oral contrast<br>* negative oral contrast utilization in PET/CT studies<br>|
| Mannitol<br>Patients who ingested mannitol as an oral contrast | Other: oral contrast<br>* negative oral contrast utilization in PET/CT studies<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| compare the performance of different negative oral contrast agents in PET/Ct studies | comparing the effect of different oral contrast on bowel distention | baseline |
Study of Naltrexone for Methamphetamine Addiction

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether methamphetamine-dependent individuals will use less methamphetamine when treated with naltrexone. The study will also investigate whether individuals with the mu opioid receptor gene variant A118G will use less methamphetamine than individuals without A118G.

Official Title
-----------------
A Pilot Trial of Naltrexone for Methamphetamine Addiction - Role of the A118G SNP

Conditions
-----------------
Methamphetamine Dependence

Intervention / Treatment
-----------------
* Drug: Naltrexone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age between 18 and 50 years Patient is agreeable to conditions of study and signs consent form

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: A118G<br> | Drug: Naltrexone<br>* 380mg extended-release, given once by intramuscular gluteal injection<br>* Other names: Vivitrex;|
| Experimental: Wild-type<br> | Drug: Naltrexone<br>* 380mg extended-release, given once by intramuscular gluteal injection<br>* Other names: Vivitrex;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| MA (-) Urine Samples |  | Twice weekly for 5 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Meth, Methamphetamine Addiction, Methamphetamine Treatment, Naltrexone, Vivitrol, A118G, OPRM1
The Combination of GnRh Analogue and Aromatase Inhibitor in Receptor Positive Premenopausal Women With Advanced Breast Cancer

Study Overview
=================
Brief Summary
-----------------
The Combination of GnRh Analogue and Aromatase Inhibitor in Receptor Positive Premenopausal Women with Advanced Breast Cancer A Prospective Trial.

Detailed Description
-----------------
The Combination of GnRh Analogue and Aromatase Inhibitor in Receptor Positive Premenopausal Women with Advanced Breast Cancer A Prospective Trial.

Official Title
-----------------
The Combination of GnRh Analogue and Aromatase Inhibitor in Receptor Positive Premenopausal Women With Advanced Breast Cancer A Prospective Trial

Conditions
-----------------
Advanced Breast Cancer

Intervention / Treatment
-----------------
* Other: GnRh Analogue and Aromatase Inhibitor


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Receptor Positive Premenopausal Women with Advanced Breast Cancer. Exclusion Criteria: Any woman other than diagnosis of Receptor Positive Premenopausal with Advanced Breast Cancer.

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: GnRh Analogue and Aromatase Inhibitor|GnRh Analogue and Aromatase Inhibitor|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Premenopausal Women with Advanced Breast Cancer
Gastrointestinal Evaluation in Young Men With Iron Deficiency Anemia

Study Overview
=================
Brief Summary
-----------------
Both upper gastrointestinal endoscopy and colonoscopy are recommended in men and post-menopausal women with iron deficiency anemia. Due to lack of data on the yield of these endoscopies in young men, they are currently investigated as older men. The aim of this study is to evaluate prospectively the prevalence of various gastrointestinal lesions in young men with iron deficiency anemia. Our hypothesis is that the diagnostic yield of colonoscopy in young anemic men without gastrointestinal symptoms is very low, especially if a potential lesion is detected during upper gastrointestinal endoscopy. Therefore, this study will try to identify predicting factors regarding the yield of both endoscopies. Another purpose is to evaluate the outcome of patients with negative endoscopic results, during a follow-up of two years.

Official Title
-----------------
Prospective Evaluation of the Gastrointestinal Tract in Young Men With Iron Deficiency Anemia

Conditions
-----------------
Anemia, Iron-Deficiency

Intervention / Treatment
-----------------
* Procedure: upper gastrointestinal endoscopy, colonoscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Men < 40 years old of age with iron deficiency. hemoglobin level less than 13 gr/dl documented during the 2 years prior to entering the study with one of the following: 1) iron level less than 45 μg /dl and transferrin saturation less than 10%; 2) ferritin level less than 20 μg/L (both documented during the 4 months prior to entering the study). Exclusion Criteria: Previously diagnosed disease that explain iron deficiency anemia Colonoscopy performed during the last 4 years Upper gastrointestinal endoscopy performed during the last 2 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: upper gastrointestinal endoscopy, colonoscopy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Anemia, Iron-Deficiency, Endoscopy, Gastrointestinal, Male, aged 18 to 40
Acromegaly - Before and After Treatment

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to investigate sleep apnea, circulation and metabolism in acromegaly before and after surgery and/or medical treatment.

Detailed Description
-----------------
Acromegaly is a rare disease caused by a growth hormone (GH) producing pituitary adenoma. Surgery is primary treatment, whereas medical treatment with a somatostatin analogue (SA), which suppresses GH secretion and reduces tumour size, is used when surgery is insufficient or unfeasible. Acromegaly is associated with metabolic abnormalities which contributes to an increased morbidity and mortality if left untreated. To which extend these abnormalities reverses after treatment, and if treatment modality influences the outcome, remain elusive. The aim of the study is to investigate sleep apnea, circulation and metabolism in acromegaly before and after surgery and/or medical treatment

Official Title
-----------------
Sleep Apnea, Circulation and Metabolism in Acromegaly - Before and After Treatment

Conditions
-----------------
Acromegaly, Growth Hormone Treatment, Sleep Apnea, Cardiovascular Diseases, Bone Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Recently diagnosed with acromegaly Age above 18 Written consent Exclusion Criteria: - Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sleep apnea | ApneaLinkAir: respiratory effort, puls, oxygen saturation, nasal flow and snoring | At baseline (time of diagnosis) and at an average of 1 years treatment | 
| Circulation | Sphygmocor: central arterial pressure and pulse wave velocity | At baseline (time of diagnosis) and at an average of 1 years treatment | 
| Bone metabolism | HRpQCT scan | At baseline (time of diagnosis) and at an average of 1 years treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Heartfunction | Echocardiography | At baseline (time of diagnosis) and at an average of 1 years treatment | 
| Substrate metabolism; signaling proteins | Western blotting | At baseline (time of diagnosis) and at an average of 1 years treatment | 
| Substrate metabolism; gene targets | qPCR | At baseline (time of diagnosis) and at an average of 1 years treatment | 
| Energy expenditure | Indirect calorimetry | At baseline (time of diagnosis) and at an average of 1 years treatment | 
| Body composition | DXA scan | At baseline (time of diagnosis) and at an average of 1 years treatment | 
| Physical activity | Sensoriband | At baseline (time of diagnosis) and at an average of 1 years treatment |
Nitrofurantoin Macrocrystals 3 Days Versus 7 Days in the Treatment of Women With Uncomplicated Cystitis

Study Overview
=================
Brief Summary
-----------------
Our guidelines in the community recommend the use of NM for the treatment of women with community acquired UTI. While the length of treatment for uncomplicated cystitis with quinolones or TMP-SMX is three days, NM is recommended for seven days. However, there are not sufficient papers that establish the optimal length of treatment with NM in this population. The aim of this proposal is to evaluate and compare NM 3 day vs. 7 day treatment for the treatment of women with uncomplicated UTI.

Detailed Description
-----------------
The aim of this proposal is to evaluate and compare NM 3 day vs. 7 day treatment for the treatment of women with uncomplicated UTI. Our design is to enroll 400 women with uncomplicated cystitis and divided according to a double-blind randomization in two groups (3 days vs. 7 days). The women will be followed 7 days and 28 days clinically and bacteriologically.

Official Title
-----------------
Nitrofurantoin Macrocrystals 3 Days Vs. 7 Days in the Treatment of Women With Uncomplicated Cystitis

Conditions
-----------------
Cystitis

Intervention / Treatment
-----------------
* Drug: NITROFURANTOIN MACROCRYSTALS


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Premenopausal healthy women Uncomplicated cystitis Exclusion Criteria: Postmenopausal women Complicated UTI Women with catheter Women with recurrent UTI Pregnancy Diabetes Mellitus

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: NITROFURANTOIN MACROCRYSTALS|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Microbiological efficacy |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical efficacy and side effects |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Uncomplicated Cystitis, Nitrofurantoin Macrocrystals
Modified Uterosacral Ligament Suspension in Vaginal Hysterectomy

Study Overview
=================
Brief Summary
-----------------
Introduction : The extraperitoneal uterosacral ligament suspension (ULS) can be performed during the removal of the uterus in vaginal hysterectomy to prevent cuff prolapse. In this study, the modified extraperitoneal ULS technique was evaluated in terms of preventing cuff prolapse. Methods / Technique : Forty patients with second and third-stage uterine prolapse who were operated were included in the study. During routine vaginal hysterectomy procedure performed on patients, after sacrouterine ligaments which are the first-bites and uteroovarian and round ligaments which are the last-bites have been sutured and knotted, these ligaments were marked with 4-distinct clemps to make the right and left, upper and lower separation. After vaginal cuff was closed the sutures hanged by the clamps were ligated together, and the cuff tissue was stretched to the apical line.

Official Title
-----------------
Modified Extraperitoneal Uterosacral Ligament Suspension in Preventing Cuff Prolapse Risk After Vaginal Hysterectomy; 4 Clamp Method

Conditions
-----------------
Modified Extraperitoneal Uterosacral Ligament Suspension, Vault Prolapse, Vaginal

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Stage 2 or 3 uterin prolapse Exclusion Criteria: contrandication for surgery

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| postoperative vaginal cuff prolapse | During two years follow up after sugery if there is vaginal cuff prolapse or not. The measurement of the vaginal cuff distance to the hymenal ring with a calculator. The units were centimeter | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Vaginal Hysterectomy